Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized placebo-controlled study of zetomipzomib in active lupus nephritis
MOH_2023-07-27_012849Phase 2Completed
- Sponsor
- Kezar Life Sciences
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zetomipzomib in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (3 arms), sponsored by Kezar Life Sciences. Started Jun 2023; status: completed.
02
Drugs
zetomipzomib
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2023-07-27_012849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-27_012849.